Catalent

Catalent, Inc. is a globally recognized Contract Development and Manufacturing Organization (CDMO) headquartered in New Jersey, USA. It partners with pharmaceutical, biotechnology, and consumer health companies to accelerate innovation across drug development, delivery, and lifecycle supply. At its core, Catalent offers integrated capabilities spanning: formulation and process development, analytical sciences, clinical trial supply and packaging, manufacturing at scale (oral, biologics, cell & gene therapy), and regulatory / supply chain support. Its expertise in drug delivery technologies—such as advanced oral systems, softgels, injectables, and ultra-high potency systems—gives partners flexibility to address complex formulation challenges. With more than 50 facilities across four continents, Catalent supports clients from early stage through commercial scale, enabling faster product launches, improved supply reliability, and regulatory compliance. The company has played a pivotal role in delivering over half of the FDA-approved drugs in recent years. Beyond manufacturing, Catalent also focuses on continuous innovation—investing in new technologies, delivery systems, and process efficiencies to meet evolving pharmaceutical demands. Its global reach, deep technical resources, and lifecycle orientation make it a trusted partner for companies aiming to bring better therapies to patients worldwide.